Novavax (NVAX) is a small-cap vaccine company, yet it has a very large long-term potential. The company has a great pipeline that is full of depth, and this pipeline should be able to create substantial value for shareholders as it progresses. Furthermore, the recent attempt to merge with Isconova AB should only help to add more depth to the pipeline. Novavax has some very interesting vaccines.
Novavax recently announced a merger with Isconova, in which Novavax will acquire all of the outstanding shares of Isconova. This merger should help to drive long-term growth, given the fact that the companies pipelines seem to compliment one another's quite nicely. The offer values Isconava at $29.6 million. Isconova's board...
Only subscribers can access this article, which is part of the PRO research library covering 3,612 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: